scholarly article | Q13442814 |
P50 | author | Daniel P Cahill | Q40711326 |
Elisabeth M Roider | Q59859356 | ||
Dan Zhao | Q79405023 | ||
P2093 | author name string | David E Fisher | |
Keith T Flaherty | |||
Robert E Gerszten | |||
William T Curry | |||
A John Iafrate | |||
Gejing Deng | |||
Shota Tanaka | |||
Andrew S Chi | |||
Tracy T Batchelor | |||
Xu Shi | |||
Jing-Ruey J Yeh | |||
Hiroaki Wakimoto | |||
Yiyun Zhang | |||
Yardena Samuels | |||
Timothy He | |||
Fares Nigim | |||
Dmitri Wiederschain | |||
Kensuke Tateishi | |||
Bailin Zhang | |||
Olivier Bedel | |||
Mara V A Koerner | |||
Lajos V Kemeny | |||
Franziska Loebel | |||
Nina Lelic | |||
Quan Ho | |||
Sudhandra Sundaram | |||
P2860 | cites work | Cancer genome landscapes | Q22242276 |
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate | Q24320239 | ||
Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas | Q24610836 | ||
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma | Q24612429 | ||
Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases | Q24632807 | ||
Recurring mutations found by sequencing an acute myeloid leukemia genome | Q24634204 | ||
An integrated genomic analysis of human glioblastoma multiforme | Q24648860 | ||
IDH1 and IDH2 mutations in gliomas | Q24648948 | ||
Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells | Q24648994 | ||
IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas | Q24656269 | ||
The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases | Q27667409 | ||
Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation | Q27684364 | ||
IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma | Q27851701 | ||
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. | Q27852141 | ||
Loss of NAPRT1 expression by tumor-specific promoter methylation provides a novel predictive biomarker for NAMPT inhibitors | Q27852577 | ||
Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells | Q28504783 | ||
AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1 | Q28506431 | ||
IDH mutation impairs histone demethylation and results in a block to cell differentiation | Q29305058 | ||
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation | Q29615366 | ||
Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy | Q29615616 | ||
Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia | Q29616650 | ||
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype | Q29617457 | ||
AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy | Q29618101 | ||
Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha | Q29619709 | ||
Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo | Q33630257 | ||
Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas. | Q33804713 | ||
IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study | Q33897586 | ||
Cancer-associated isocitrate dehydrogenase 1 (IDH1) R132H mutation and d-2-hydroxyglutarate stimulate glutamine metabolism under hypoxia. | Q34140953 | ||
IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours | Q34186353 | ||
5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft. | Q34374136 | ||
Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma | Q34391844 | ||
Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome | Q34602582 | ||
Analysis of the IDH1 codon 132 mutation in brain tumors | Q34873009 | ||
Glioma cells with the IDH1 mutation modulate metabolic fractional flux through pyruvate carboxylase | Q35268977 | ||
Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of α-ketoglutarate to citrate to support cell growth and viability | Q35621293 | ||
Reductive carboxylation supports growth in tumour cells with defective mitochondria. | Q35683311 | ||
Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer | Q35842729 | ||
Cancer-associated isocitrate dehydrogenase mutations inactivate NADPH-dependent reductive carboxylation | Q35922402 | ||
Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) activity by small molecule GMX1778 regulates reactive oxygen species (ROS)-mediated cytotoxicity in a p53- and nicotinic acid phosphoribosyltransferase1 (NAPRT1)-dependent manner | Q36052583 | ||
IDH1 mutations alter citric acid cycle metabolism and increase dependence on oxidative mitochondrial metabolism | Q36948088 | ||
Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition | Q37220129 | ||
(R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible | Q37332185 | ||
Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine. | Q37381606 | ||
The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors | Q37410764 | ||
Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors | Q37447217 | ||
Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. | Q37613957 | ||
IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics | Q37734751 | ||
The NAD metabolome--a key determinant of cancer cell biology | Q38047182 | ||
Medicinal chemistry of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors | Q38107280 | ||
Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype. | Q38874166 | ||
Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines. | Q38884358 | ||
Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. | Q39394926 | ||
Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production | Q39458545 | ||
Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. | Q39636555 | ||
FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis | Q40617327 | ||
WK175, a novel antitumor agent, decreases the intracellular nicotinamide adenine dinucleotide concentration and induces the apoptotic cascade in human leukemia cells | Q40748736 | ||
Selective inhibition of mutant isocitrate dehydrogenase 1 (IDH1) via disruption of a metal binding network by an allosteric small molecule | Q41906201 | ||
Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors | Q43244943 | ||
SDH5 mutations and familial paraganglioma: somewhere Warburg is smiling | Q43280621 | ||
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. | Q45953731 | ||
Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma | Q48568468 | ||
CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo | Q73229795 | ||
IDH1 inhibitor shows promising early results | Q86519666 | ||
P433 | issue | 6 | |
P304 | page(s) | 773-784 | |
P577 | publication date | 2015-12-01 | |
P1433 | published in | Cancer Cell | Q280018 |
P1476 | title | Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion | |
P478 | volume | 28 |
Q33698756 | 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity. |
Q47846484 | 2-hydroxyglutarate-mediated autophagy of the endoplasmic reticulum leads to an unusual downregulation of phospholipid biosynthesis in mutant IDH1 gliomas |
Q47123308 | A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma |
Q47989563 | Adaptive Evolution of the GDH2 Allosteric Domain Promotes Gliomagenesis by Resolving IDH1R132H-Induced Metabolic Liabilities |
Q91736543 | Altered cellular metabolism in gliomas - an emerging landscape of actionable co-dependency targets |
Q38961789 | Altered metabolite levels in cancer: implications for tumour biology and cancer therapy. |
Q37534085 | An NAD+-dependent transcriptional program governs self-renewal and radiation resistance in glioblastoma |
Q55457331 | Association between mutant IDHs and tumorigenesis in gliomas. |
Q50033966 | Beyond Brooding on Oncometabolic Havoc in IDH-Mutant Gliomas and AML: Current and Future Therapeutic Strategies. |
Q89497288 | Beyond Energy Metabolism: Exploiting the Additional Roles of NAMPT for Cancer Therapy |
Q55456962 | Biological Role and Therapeutic Potential of IDH Mutations in Cancer. |
Q91775513 | CRISPR Editing of Mutant IDH1 R132H Induces a CpG Methylation-Low State in Patient-Derived Glioma Models of G-CIMP |
Q64277360 | Cancer-associated mutation and beyond: The emerging biology of isocitrate dehydrogenases in human disease |
Q58609746 | Cell surface Notch ligand DLL3 is a therapeutic target in isocitrate dehydrogenase mutant glioma |
Q38405744 | Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair |
Q64242985 | Cholesterol Metabolism: A Potential Therapeutic Target in Glioblastoma |
Q46232869 | Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant IDH1. |
Q38771020 | Correlation of immune phenotype with IDH mutation in diffuse glioma. |
Q47169542 | Current trends in mouse models of glioblastoma. |
Q53433176 | D-2-Hydroxyglutarate Is Necessary and Sufficient for Isocitrate Dehydrogenase 1 Mutant-Induced MIR148A Promoter Methylation. |
Q61796395 | DNA demethylation is associated with malignant progression of lower-grade gliomas |
Q99609760 | Development of Autophagy Signature-Based Prognostic Nomogram for Refined Glioma Survival Prognostication |
Q52604402 | Double-barreled gun: Combination of PARP inhibitor with conventional chemotherapy. |
Q92059824 | Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemia |
Q26741300 | Emerging therapeutic roles for NAD(+) metabolism in mitochondrial and age-related disorders |
Q50782958 | Exploiting tumor vulnerabilities: NAD(+)-depleting agents combined with anti-tumor drugs as innovative strategy to treat hematological malignancies. |
Q89534126 | Extracellular glutamate and IDH1R132H inhibitor promote glioma growth by boosting redox potential |
Q90025515 | Friend or foe-IDH1 mutations in glioma 10 years on |
Q91286849 | Functional and topographic effects on DNA methylation in IDH1/2 mutant cancers |
Q57048305 | Genetic Abnormalities, Clonal Evolution, and Cancer Stem Cells of Brain Tumors |
Q64056689 | Glioblastoma Stem- Cells, Metabolic Strategy to Kill a Challenging Target |
Q47894744 | Glioma CpG Island Methylator Phenotype (G-CIMP): Biological and Clinical Implications |
Q90642725 | Glucose Metabolism on Tumor Plasticity, Diagnosis, and Treatment |
Q99564929 | Glutamine reliance in cell metabolism |
Q90425302 | Gray Areas in the Gray Matter: IDH1/2 Mutations in Glioma |
Q91934018 | IDH mutation in glioma: molecular mechanisms and potential therapeutic targets |
Q28066926 | IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives |
Q58738690 | IDH1 is intrinsically tumor-suppressive but functionally attenuated by the glutamate-rich cerebral environment |
Q91643878 | Identification of Circulating Genomic and Metabolic Biomarkers in Intrahepatic Cholangiocarcinoma |
Q90516025 | Illuminating NAD+ Metabolism in Live Cells and In Vivo Using a Genetically Encoded Fluorescent Sensor |
Q42652909 | Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL. |
Q91761588 | Inhibition of PARP Sensitizes Chondrosarcoma Cell Lines to Chemo- and Radiotherapy Irrespective of the IDH1 or IDH2 Mutation Status |
Q38720863 | Inhibitor of Nicotinamide Phosphoribosyltransferase Sensitizes Glioblastoma Cells to Temozolomide via Activating ROS/JNK Signaling Pathway. |
Q32173000 | Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles |
Q57261202 | Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles |
Q50065686 | In Vivo Imaging of Glutamine Metabolism to the Oncometabolite 2-Hydroxyglutarate in IDH1/2 Mutant Tumors |
Q33763540 | Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma |
Q98778655 | Isocitrate dehydrogenase 1 mutation enhances 24(S)-hydroxycholesterol production and alters cholesterol homeostasis in glioma |
Q58728288 | Isocitrate dehydrogenase 1 mutation sensitizes intrahepatic cholangiocarcinoma to the BET inhibitor JQ1 |
Q47605895 | Isocitrate dehydrogenase-mutant glioma: Evolving clinical and therapeutic implications. |
Q41247181 | Isocitrate dehydrogenases in physiology and cancer: biochemical and molecular insight |
Q33642585 | Meat Intake and the Dose of Vitamin B3 - Nicotinamide: Cause of the Causes of Disease Transitions, Health Divides, and Health Futures? |
Q92875529 | Metabolic Abnormalities in Glioblastoma and Metabolic Strategies to Overcome Treatment Resistance |
Q99549175 | Metabolic Constrains Rule Metastasis Progression |
Q52716898 | Metabolic characterization of isocitrate dehydrogenase (IDH) mutant and IDH wildtype gliomaspheres uncovers cell type-specific vulnerabilities. |
Q91013912 | Metabolic rearrangements in primary liver cancers: cause and consequences |
Q49835155 | Metabolism, Activity, and Targeting of D- and L-2-Hydroxyglutarates |
Q49028007 | Metabolism: Totally addicted to NAD(.). |
Q89758958 | Metastatic pheochromocytoma and paraganglioma: proceedings of the MEN2019 workshop |
Q60907690 | Mitochondrial VDAC1 Silencing Leads to Metabolic Rewiring and the Reprogramming of Tumour Cells into Advanced Differentiated States |
Q93333875 | Molecular Pathogenesis of Low-Grade Glioma |
Q36805635 | Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer |
Q46594099 | Molecular and Genetic Determinants of Glioma Cell Invasion |
Q92630717 | Mutant IDH1 Depletion Downregulates Integrins and Impairs Chondrosarcoma Growth |
Q92328393 | Mutant IDH1 Differently Affects Redox State and Metabolism in Glial Cells of Normal and Tumor Origin |
Q42259199 | Mutant IDH1 regulates the tumor-associated immune system in gliomas |
Q64974414 | Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics. |
Q48228203 | Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence. |
Q37230411 | Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma |
Q60958368 | NAD Metabolism in Cancer Therapeutics |
Q90284271 | NAD metabolic dependency in cancer is shaped by gene amplification and enhancer remodelling |
Q89944614 | NAD- and NADPH-Contributing Enzymes as Therapeutic Targets in Cancer: An Overview |
Q92860042 | NAMPT and NAPRT, Key Enzymes in NAD Salvage Synthesis Pathway, Are of Negative Prognostic Value in Colorectal Cancer |
Q95936527 | Nanomedicine-based immunotherapy for central nervous system disorders |
Q33703205 | Nicotinamide metabolism regulates glioblastoma stem cell maintenance |
Q92256258 | Nicotinamide phosphoribosyltransferase is a molecular target of potent anticancer agents identified from phenotype-based drug screening |
Q47131402 | Novel NAPRT specific antibody identifies small cell lung cancer and neuronal cancers as promising clinical indications for a NAMPT inhibitor/niacin co-administration strategy |
Q92380923 | OT-82, a novel anticancer drug candidate that targets the strong dependence of hematological malignancies on NAD biosynthesis |
Q57796367 | Oncogenic R132 IDH1 Mutations Limit NADPH for De Novo Lipogenesis through (D)2-Hydroxyglutarate Production in Fibrosarcoma Sells |
Q61811738 | PARP Inhibitors for Sensitization of Alkylation Chemotherapy in Glioblastoma: Impact of Blood-Brain Barrier and Molecular Heterogeneity |
Q42580090 | PIK3CA mutant tumors depend on oxoglutarate dehydrogenase |
Q87892601 | Parahydrogen-Based Hyperpolarization for Biomedicine |
Q99240595 | Patient-derived cells from recurrent tumors that model the evolution of IDH-mutant glioma |
Q41064782 | Perspectives on investigational drugs and immunotherapies for glioblastoma |
Q52584624 | Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate. |
Q39417407 | Pharmacotherapy of Glioblastoma: Established Treatments and Emerging Concepts |
Q51760444 | Pivotal role of NAMPT in the switch of melanoma cells toward an invasive and drug-resistant phenotype. |
Q64972730 | Radiotherapy resistance in chondrosarcoma cells; a possible correlation with alterations in cell cycle related genes. |
Q38757450 | Rapid Conversion of Mutant IDH1 from Driver to Passenger in a Model of Human Gliomagenesis |
Q46614710 | Reverse engineering the cancer metabolic network using flux analysis to understand drivers of human disease |
Q90225264 | Sestrins as a Therapeutic Bridge between ROS and Autophagy in Cancer |
Q93027996 | Subcellular compartmentalization of NAD+ and its role in cancer: A sereNADe of metabolic melodies |
Q89486322 | Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate |
Q38849515 | Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future |
Q47646742 | Targeting Metabolism for Cancer Therapy. |
Q52325957 | Targeting NAD+/PARP DNA repair pathway as a novel therapeutic approach to SDHB-mutated cluster I pheochromocytoma and paraganglioma. |
Q38821103 | Targeting the cancer epigenome for therapy |
Q46774124 | Targeting the vulnerability to NAD+ depletion in B-cell acute lymphoblastic leukemia |
Q42511174 | The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in IDH1-Mutant Cancers and Potentiates NAD+ Depletion-Mediated Cytotoxicity |
Q38658458 | The emerging role and targetability of the TCA cycle in cancer metabolism. |
Q90574839 | The oncometabolite 2-hydroxyglutarate produced by mutant IDH1 sensitizes cells to ferroptosis |
Q91843726 | Transcriptomic Analysis of Glioma Based on IDH Status Identifies ACAA2 as a Prognostic Factor in Lower Grade Glioma |
Q39130440 | Understanding the Intersections between Metabolism and Cancer Biology |
Q47713415 | Wild-type and mutated IDH1/2 enzymes and therapy responses. |
Q90736012 | mTORC2/Rac1 Pathway Predisposes Cancer Aggressiveness in IDH1-Mutated Glioma |